[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478000":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":11,"centralContacts":61,"locations":67,"responsibleParty":86,"collaborators":11,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":11,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":11,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":11,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY",[8,17,21,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"IBI351 in combination with pemetrexed and cis-platinum\u002Fcarboplatin (the subject with PD-L1 TPS\u003C1%)","EXPERIMENTAL",null,[13,14,15,16],"Drug: IBI351","Drug: pemetrexed","Drug: Carboplatin","Drug: cis-platinum",{"label":18,"type":10,"description":11,"interventionNames":19},"IBI351 in combination with Cetuximab",[13,20],"Drug: Cetuximab",{"label":22,"type":10,"description":11,"interventionNames":23},"IBI351 monotherapy",[13],{"label":25,"type":10,"description":11,"interventionNames":26},"IBI351 in combination with Sintilimab",[13,27],"Drug: Sintilimab",{"label":29,"type":10,"description":11,"interventionNames":30},"IBI351 in combination with pemetrexed and cis-platinum\u002Fcarboplatin(the subject with PD-L1 TPS 1-49%)",[13,14,15,16],[32,39,43,47,51,57],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","IBI351","recommended dose, po",[18,25,9,29,22],[38],"GFH925",{"type":33,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"Cetuximab","500mg\u002Fm\\^2, Q2W, day1, i.v.",[18],{"type":33,"name":44,"description":45,"armGroupLabels":46,"otherNames":11},"pemetrexed","500mg\u002Fm\\^2, Q3W, day1, i.v.",[9,29],{"type":33,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"Carboplatin","AUC=5, Q3W, day1, i.v.",[9,29],{"type":33,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"Sintilimab","200mg, Q3W, day1, i.v.",[25],[56],"IBI308",{"type":33,"name":58,"description":59,"armGroupLabels":60,"otherNames":11},"cis-platinum","75mg\u002Fm\\^2, Q3W, day1, i.v.",[9,29],[62],{"name":63,"role":64,"phone":65,"phoneExt":11,"email":66},"Haiyan Zhu","CONTACT","0512-69566088","haiyan.zhu@innoventbio.com",[68],{"facility":69,"status":70,"city":71,"state":72,"zip":11,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"Jilin Province Cancer Hospital","RECRUITING","Jilin City","Changchun","China","CN",{"type":76,"coordinates":77},"Point",[78,79],126.5608,43.84652,{"lat":79,"lon":78},[82],{"name":83,"role":64,"phone":84,"phoneExt":11,"email":85},"Ying Cheng","0431-80596315","jl.cheng@163.com",{"type":87,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100478000","phase-1-efficacy-and-safety-of-ibi351-in-combination-with-chemotherapy-in-advanced-non-squamous-non-small-cell-lung-cancer-subjects-with-kras-g12c-mutation-100478000",false,"NCT05504278","Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation","An Open-label, Multi-center Phase Ib\u002FIII Study Evaluating the Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of nonsquamous NSCLC with KRAS G12C mutation\n2. Unresectable or metastatic disease\n3. Adequate organ function\n4. Not received any systemic antitumor therapy for locally advanced or metastatic non-squamous NSCLC previously.\n\nExclusion Criteria:\n\n1. History of intestinal disease or major gastric surgery or inability to swallow oral medications\n2. Prior therapy with agents targeting KRAS G12C mutation (e.g., AMG 510).\n3. Active brain metastases.","ALL","18 Years","75 Years",{"count":99,"type":100},144,"ESTIMATED","INTERVENTIONAL",[103],"PHASE1","This Phase Ib\u002FIII study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.",[106],"Advanced Non-Small Cell Lung Cancer","2025-01-22",{"date":109,"type":110},"2025-01-27","ACTUAL",{"date":112,"type":110},"2022-09-20",{"date":114,"type":100},"2027-07-31",{"name":5,"class":6},1]